A team of scientists has solved a decades-old scientific puzzle by identifying the genetic basis of the AnWj blood group antigen, establishing a new human blood group system named MAL. This breakthrough enables better detection and protection for the very rare individuals lacking AnWj, reducing risk during blood transfusions.
- AnWj antigen linked to the MAL gene after 50 years of mystery
- Over 99.9% of people have the AnWj antigen on red blood cells
- New blood group system MAL aids rare blood matching and transfusion safety
What happened
Scientists have successfully identified the genetic origin of the AnWj antigen, a marker found on red blood cells discovered in 1972. This breakthrough came after many years of research involving whole exome sequencing, which examines the protein-coding parts of DNA. This technique highlighted the MAL gene as the source of the AnWj antigen. Researchers observed that individuals with a hereditary lack of AnWj antigen had mutations disrupting the MAL gene, confirming its role.
By studying red blood cells from several AnWj-negative people, including the first person identified with this rare blood type in the 1970s, scientists demonstrated that the MAL gene produces a protein called Mal. This small membrane protein is necessary for the presence of the AnWj antigen on red blood cells. Introducing the normal MAL gene into laboratory cells restored AnWj reactivity, conclusively linking MAL to the blood group system now formally recognized as ISBT 047.
Why it feels good
This discovery is a significant step in understanding the complexity of human blood beyond the well-known ABO and Rh groups. While the vast majority of people have the AnWj antigen, a very small minority do not, and this can cause serious complications in blood transfusions. Knowing the exact genetic cause helps medical professionals more easily identify and protect these rare patients.
The new MAL blood group system gives clinicians a precise method to find donors compatible with AnWj-negative recipients, reducing the risk of dangerous immune reactions during transfusions. It also sheds light on the varied biological markers on red blood cells, expanding the toolkit to safely manage blood donations and transfusions for those with unique blood types.
What to enjoy or watch next
As blood transfusion medicine continues to evolve, this discovery opens doors to further research on other rare blood antigens, improving safety and outcomes worldwide. Scientists and healthcare providers can now develop better screening tests and donor registries focusing on MAL and similar rare markers, enhancing personalized care in transfusion therapies.
Looking ahead, attention may turn to exploring how suppression of AnWj expression due to certain diseases can be distinguished from inherited absence. Continued collaboration among global blood research centers promises ongoing improvements in the understanding and treatment of blood-related disorders, benefiting patients with uncommon blood group variations everywhere.